## Contents

### Part I Clinical Aspects

1 History of the Israeli Cohort of Laron Syndrome Patients (1958–2009) ........................................ 3
   Zvi Laron

2 Early Investigations: Characterizations of the Circulating Growth Hormone .................................... 9
   Zvi Laron

3 Clinical Evidence of Growth Hormone Resistance in Patients with Laron Syndrome ......................... 21
   Zvi Laron

4 Diagnosis of Laron Syndrome ............................................................... 27
   Zvi Laron

5 Genetic Aspects .............................................................................. 29
   Orit Shevah and Zvi Laron
   5.1 Genetic Investigations ................................................................ 29
   Orit Shevah and Zvi Laron
   5.2 Hypothesis of the Origin of Laron Syndrome ......................... 47
   Zvi Laron and Orit Shevah
   5.3 Are the Pygmies Laron Syndrome Patients? ......................... 50
   Zvi Laron

6 Clinical Evaluation ................................................................. 53
   Zvi Laron

7 Perinatal Development in Laron Syndrome ................................. 59
   Zvi Laron and Rivka Kauli

8 Linear Growth Pattern of Untreated Laron Syndrome Patients ................................................... 63
   Zvi Laron and Rivka Kauli
9 Head Shape, Size, and Growth of Untreated Patients with Laron Syndrome .............................................. 91
Zvi Laron and Rivka Kauli

10 Sexual Development in Patients with Laron Syndrome ................................................................. 101
Zvi Laron and Rivka Kauli

11 Sex Hormone Binding Proteins and Sex Hormones in Untreated and IGF-I Treated Patients with Laron Syndrome ................................................................. 119
Zvi Laron and Rivka Kauli

11.1 Sex Hormone Binding Proteins ............................................. 119
Zvi Laron

11.2 Sex Hormones in Untreated Patients with Laron Syndrome .... 121
Zvi Laron and Rivka Kauli

12 The Adipose Tissue in Patients with Laron Syndrome ...................................................................... 125
Zvi Laron

13 Investigations to Determine the Cause of Obesity in Patients with Laron Syndrome ................. 135
Zvi Laron, Shira Ginsberg, and Nahum Vaisman

14 Nonalcoholic Fatty Liver Disease (NAFLD) in Patients with Laron Syndrome .............................. 143
Zvi Laron

15 Serum Lipids in Patients with Laron Syndrome .............................................................................. 149
Zvi Laron

16 Adiponectin and Leptin in Laron Syndrome ................................................................................. 157
Zvi Laron and Hannah Kanety

17 Muscle Force and Endurance in Untreated Adult and IGF-I Treated Children with Laron Syndrome ........................................................................................................... 161
Zvi Laron

18 Bone Mineral Density in Untreated and IGF-I or Alendronate-Treated Patients with Laron Syndrome ........................................................................................................... 165
Zvi Laron

19 Muscle–Bone Relationship in Patients with Laron Syndrome .............................................................. 171
Yoram Epstein, Amir Hadid, Zvi Laron, Daniel S. Moran, and Nahum Vaisman

19.1 Bone Characteristics ......................................................... 171
Yoram Epstein, Amir Hadid, Zvi Laron, and Daniel S. Moran

19.2 Lean Body Mass (LBM) in Patients with Laron Syndrome . . . . . . . . 173
Zvi Laron and Nahum Vaisman
20 Imaging Findings in Laron Syndrome
Liora Kornreich and Zvi Laron

21 Ocular Findings in Laron Syndrome
Dan H. Bourla and Dov Weinberger

22 Hearing in Patients with Laron Syndrome
Zvi Laron, Omer Zarchi, and Joseph Attias

23 The Teeth in Patients with Laron Syndrome
Zvi Laron

24 Hair, Skin, and Nails in Patients with Laron Syndrome
Zvi Laron

25 Hand, Foot, and Organ Size and Growth in Untreated and IGF-I Treated Patients with Laron Syndrome
Zvi Laron and Aviva Silbergeld

25.1 Hand Size and Growth of Untreated and IGF-I Treated Laron Syndrome Patients
Zvi Laron

25.2 Foot Size and Growth in Untreated and IGF-I-Treated Patients with Laron Syndrome
Zvi Laron and Aviva Silbergeld

25.3 Organ Size
Zvi Laron

26 Lifelong Serum Growth Hormone Levels in Patients with Laron Syndrome
Zvi Laron and Orly Efros

27 IGF-I Binding Proteins in Laron Syndrome
Zvi Laron

28 Serum Prolactin in Untreated and IGF-I Treated Patients with Laron Syndrome
Zvi Laron and Orly Efros

29 Thyroid Hormones in Untreated and IGF-I Treated Patients with Laron Syndrome
Zvi Laron and Rivka Kauli

30 Insulin Secretion and Carbohydrate Metabolism in Patients with Laron Syndrome: From Hypoglycemia to Diabetes Mellitus
Zvi Laron

31 Liver Enzymes in Patients with Laron Syndrome
Zvi Laron and Tsvia Karmon
32 The Hematopoietic System in Patients with Laron Syndrome ........ 283
Zvi Laron

33 Cardiovascular Aspects in Laron Syndrome Patients ............... 293
Mickey Scheinowitz, Micha S. Feinberg, Michael Shechter, Zvi Laron, and Rivka Kauli

33.1 Heart Functions in Untreated and IGF-I-Treated Patients with Laron Syndrome ......................... 293
Mickey Scheinowitz, Micha S. Feinberg, and Zvi Laron

33.2 Endothelial Function in Adults with Laron Syndrome (Primary Growth Hormone Insensitivity) .......... 298
Michael Shechter and Zvi Laron

33.3 Intimal Thickness of the Extracranial Arteries in Untreated Adult Patients with Laron Syndrome .......... 300
Zvi Laron

33.4 Cardiovascular Disease ........................................ 303
Zvi Laron and Rivka Kauli

34 Kidney Functions in Untreated and IGF-I Treated Patients with Laron Syndrome ......................... 307
Zvi Laron

35 Sleep and Sleep Disorders in Patients with Laron Syndrome ...... 317
Zvi Laron, Rivka Kauli, and Eyal Rosenzweig

35.1 Sleep Quality ..................................................... 317
Zvi Laron and Rivka Kauli

35.2 Severe Obstructive Sleep Apnea (OSA) ........................ 318
Zvi Laron

35.3 Additional Polysomnographic Examinations of Patients with Laron Syndrome ........................... 318
Eyal Rosenzweig and Zvi Laron

36 Neurological Aspects in Laron Syndrome .......................... 321
Zvi Laron

37 Orthopedic Problems in Laron Syndrome .......................... 323
Zvi Laron and Rivka Kauli

38 Psychological Aspects in Patients with Laron Syndrome ......... 325
Zvi Laron

39 Adjustment and Rehabilitation Problems of Children, Adolescents, and Adults with Laron Syndrome .......... 335
Zvi Laron

40 Laron Syndrome Patients with Congenital IGF-I Deficiency Seem Protected from Malignant Diseases .... 339
Zvi Laron, Rachel Steuerman, and Orit Shevah
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>41</td>
<td>Lifespan and Mortality of Patients with Laron Syndrome</td>
<td>341</td>
</tr>
<tr>
<td></td>
<td>Zvi Laron</td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>IGF-I Treatment of Patients with Laron Syndrome</td>
<td>343</td>
</tr>
<tr>
<td></td>
<td>Zvi Laron</td>
<td></td>
</tr>
<tr>
<td>43</td>
<td>IGF-I Stimulation of Head Growth in Patients with Laron Syndrome</td>
<td>381</td>
</tr>
<tr>
<td></td>
<td>Zvi Laron</td>
<td></td>
</tr>
<tr>
<td>44</td>
<td>Effects of Long-Term Administration of IGF-I on the Adipose Tissue</td>
<td>389</td>
</tr>
<tr>
<td></td>
<td>and Carbohydrate Metabolism in Children with Laron Syndrome</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Zvi Laron</td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>Comparison of the Growth Promoting Response of IGF-I in Children</td>
<td>409</td>
</tr>
<tr>
<td></td>
<td>with Laron Syndrome with that of hGH in Children with Isolated GH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deficiency</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Zvi Laron</td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>IGF-I Treatment of Adult Patients with Laron Syndrome</td>
<td>413</td>
</tr>
<tr>
<td></td>
<td>Zvi Laron</td>
<td></td>
</tr>
<tr>
<td>47</td>
<td>Adverse Effects Encountered During IGF-I Treatment of Patients with</td>
<td>419</td>
</tr>
<tr>
<td></td>
<td>Laron Syndrome</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Zvi Laron</td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>Summary of the Clinical History: The Laron Syndrome Clock</td>
<td>425</td>
</tr>
<tr>
<td></td>
<td>Zvi Laron</td>
<td></td>
</tr>
<tr>
<td>Part II</td>
<td>The Growth Hormone Receptor “Null” Mouse or the Laron Mouse</td>
<td></td>
</tr>
<tr>
<td>49</td>
<td>The Laron Mouse</td>
<td>429</td>
</tr>
<tr>
<td></td>
<td>John J. Kopchick and John D. Blischak</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>Role of GH/IGF-I Deficiency in Aging</td>
<td>433</td>
</tr>
<tr>
<td></td>
<td>Edward O. List</td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>Body Composition, Adipose Tissue, and Energy Balance</td>
<td>441</td>
</tr>
<tr>
<td></td>
<td>Darlene E. Berryman</td>
<td></td>
</tr>
<tr>
<td>52</td>
<td>Metabolism and Metabolic Regulation</td>
<td>451</td>
</tr>
<tr>
<td></td>
<td>Lucila Sackmann-Sala, D. R. Bailey Miles, and John J. Kopchick</td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>Skeletal Muscle</td>
<td>465</td>
</tr>
<tr>
<td></td>
<td>Juan Ding and John J. Kopchick</td>
<td></td>
</tr>
<tr>
<td>Section</td>
<td>Title</td>
<td>Page</td>
</tr>
<tr>
<td>---------</td>
<td>---------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>54</td>
<td>Cardiac Function in GHR−/− Mice</td>
<td>473</td>
</tr>
<tr>
<td></td>
<td>Diana Cruz-Topete and John J. Kopchick</td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>Bone</td>
<td>481</td>
</tr>
<tr>
<td></td>
<td>Shigeru Okada and Jacob Wright-Piekarski</td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>GHR Knockout and the CNS</td>
<td>489</td>
</tr>
<tr>
<td></td>
<td>Elahu S. Gosney and John J. Kopchick</td>
<td></td>
</tr>
<tr>
<td>57</td>
<td>Cancer</td>
<td>495</td>
</tr>
<tr>
<td></td>
<td>Brian D. Bower and John J. Kopchick</td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>Reproduction</td>
<td>507</td>
</tr>
<tr>
<td></td>
<td>Bruce Kelder</td>
<td></td>
</tr>
<tr>
<td>59</td>
<td>Conclusions and Future Studies</td>
<td>513</td>
</tr>
<tr>
<td></td>
<td>John J. Kopchick, Hiroyoshi Tanda, Darlene Berryman,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Zvi Laron</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Appendix</td>
<td>521</td>
</tr>
<tr>
<td></td>
<td>Index</td>
<td>525</td>
</tr>
</tbody>
</table>
Laron Syndrome - From Man to Mouse
Lessons from Clinical and Experimental Experience
Laron, Z.; Kopchick, J. (Eds.)
2011, XIV, 531 p., Hardcover
ISBN: 978-3-642-11182-2